Clinical Trials Logo
  1. Home
  2. Malignancies
  3. NCT03005782

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Malignancies Clinical Trial

Official title:
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies

Clinical Trial Summary

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03005782
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date November 7, 2016
Completion date April 2, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT03236857 - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Phase 1
Not yet recruiting NCT05602103 - Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
Terminated NCT00329329 - Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies Phase 1
Completed NCT00316511 - Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Phase 1
Withdrawn NCT05253105 - A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies Phase 1
Completed NCT02521389 - Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 Phase 1
Completed NCT01407380 - Study of PWT33597 Mesylate in Subjects With Advanced Malignancies Phase 1
Completed NCT01404728 - Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy N/A
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2
Not yet recruiting NCT05929495 - Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma Phase 2
Completed NCT02257476 - Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Phase 1
Completed NCT00320827 - Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) Phase 1